Please login to the form below

Not currently logged in

Abbott to acquire Facet Biotech

Abbott is to acquire Facet Biotech in a deal valued at approximately $722m, strengthening Abbott's capabilities in biologics in immunology and oncology

Abbott is to acquire Californian-based Facet Biotech in a deal valued at approximately $722m. The move will strengthen Abbott's capabilities in biologics in immunology and oncology.

The acquisition gives Abbott access to daclizumab, a mid-stage biologic being developed in collaboration with Biogen Idec for the treatment of patients with multiple sclerosis. The drug is expected to move into phase III testing in the second quarter of 2010.

Facet's oncology portfolio includes several compounds being developed in collaboration with other partners, and will complement Abbott's own compounds in mid- to late-stage trials, including ABT-263, ABT-888, and ABT-869.

Under the terms of the agreement, Abbott will begin a tender offer to purchase all outstanding shares in Facet Biotech at $27 per share in cash, resulting in a net cost of about $450m. The stock offer represents a 67 per cent premium to Facet's closing share value on Tuesday. In addition, the purchase price includes $272m, representing Facet Biotech's projected cash and securities.

The deal is expected to close in the second quarter of 2010.

10th March 2010


Featured jobs

Subscribe to our email news alerts


Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...